Patients with refractory/relapsing lymphoma are rarely cured by chemotherapy. High-dose chemotherapy (HDC) for tumor debulking followed by reduced-intensity conditioning (RIC) hematopoietic stem-cell transplantation (HSCT) has been advocated as a concept. We previously treated 10 patients (group A) with BEAM chemotherapy followed by delayed RIC HSCT at day 28. We now report on the subsequent 11 patients receiving BEAM followed immediately by fludarabine/total body irradiation and allogeneic HSCT (group B), and compare the outcome to group A patients. Non-hematological toxicity before engraftment was comparable, only gut toxicity was higher in group B. Days in aplasia, days on antibiotics and length of hospital stay were significantly longer in group A. Cumulative incidence of acute (GvHD) Xgrade II and incidence of chronic GvHD were lower in group B. At last follow-up, seven patients in group A were alive, with six of them in complete remission. In group B, nine patients were alive, seven of them in complete remission. No significant difference in estimated 3-year overall survival was seen. These data challenge the initial concept of debulking first and delaying allogeneic RIC HSCT. Allogeneic HSCT with standard BEAM conditioning is a valid alternative for patients with resistant/relapsed lymphoma, which might be considered earlier in the disease course.
Introduction
Despite advances of the increased cure rate in malignant lymphomas, patients with refractory or relapsing disease represent a population with a grim prognosis. The use of high-dose chemotherapy (HDC) with autologous stem-cell support has improved outcome in these patients, 1 but relapse is common due to residual disease and contamination of the graft with malignant cells. 2 Additionally, collection of a sufficient number of progenitor cells is often not possible because of damage to the stem-cell compartment due to extensive pretreatment or infiltration of the bone marrow. 3 Allogeneic hematopoietic stem-cell transplantation (HSCT) represents an alternative, providing a tumor-free graft and the additional advantage of an immunologically mediated graft-versus-lymphoma (GvL) effect. 4 Treatment-related mortality (TRM) rates after myeloablative conditioning regimens have historically been high, offsetting the advantages over auto-grafting. 5, 6 The advent of reduced-intensity conditioning (RIC) regimens allowing stable engraftment after administration of nonmyeloablative doses of radio-chemotherapy has renewed interest in allogeneic transplantation as a treatment option for patients with lymphoma. [7] [8] [9] However, as these types of transplants rely solely on the GvL effect for tumor eradication, and as patients deemed as candidates for allogeneic transplantation typically suffer from advanced disease, relapse rates have been high. 10 Autologous HSCT for tumor debulking followed by RIC HSCT has been advocated as a novel concept for patients with advanced lymphoma, providing the tumor reduction before HSCT and giving the necessary time for the GvL-effect to develop.
Results of a planned interim analysis after 10 patients with relapsed/refractory lymphoma treated with BEAM HDC for initial cytoreduction without autologous stem-cell rescue, followed by RIC allogeneic HSCT at day 28 after BEAM have been previously published. 14 Our report showed that the prolonged aplasia with this regimen was manageable, but infectious complications were frequent. Additionally, our initial hope of preventing graft-versushost disease (GvHD) with this approach by infusing allogeneic stem cells after declining of the cytokine storm was not fulfilled: all but one patient in the initial cohort suffered from acute GvHD grade II or higher, and all patients at risk developed chronic GvHD. However, tumor control was very encouraging; six of seven eligible patients achieved durable complete remission. This finding confirmed previous reports on allogeneic grafting in patients with refractory lymphoma, and suggests a potent GvL effect, that comes at the price of a substantial rate of acute GvHD. 15 As our hopes of reduced GvHD with this approach were not substantiated, the protocol was modified by removing the interval between cytoreductive HDC and immunosuppressive conditioning for HSCT, as GvHD rates were not lower than expected in the initial protocol. The rationale of using BEAM followed immediately by 2 Gy total body irradiation (TBI) and fludarabine was to guarantee engraftment, as BEAM alone has been reported to be insufficiently immunosuppressive for stable engraftment in some patients. 16 Furthermore, single dose 2 Gy TBI and fludarabine are expected to add little to the toxicity induced by BEAM.
With this modified condensed protocol, we aimed to reduce days in aplasia, decrease the rate of infectious complications and shorten the length of hospitalization.
In this study, we report an updated follow-up of the previously published cohort. Additionally, we present the outcome of 11 new patients treated according to the modified condensed protocol, and compare the outcome of the patients transplanted according to the modified protocol with that of patients treated previously with cytoreduction and delayed transplantation.
Patients and methods
This was a two-phase, non-randomized, single center, prospective feasibility study, comparing outcome of patients treated according to the original protocol (group A) with that of patients transplanted according to the modified protocol (group B).
All patients gave written informed consent. The chemotherapy/conditioning regimens 'BEAM' and Fludarabine -2 Gy TBI are considered standard chemotherapy/conditioning regimens in our internal handbook of the stem-cell transplant unit. The handbook is revised on a regular basis and approved by the Ethics Committee.
The first 10 patients (group A) received HDC using BEAM without autologous stem-cell support and were given an allogeneic T-replete RIC HSCT, 28 days later, after non-myeloablative conditioning. 14 . Allogeneic RIC HSCT was performed on day þ 28 of BEAM after using fludarabine 30 mg/m 2 on 3 consecutive days i.v. and 2 Gy TBI for conditioning. Cyclosporine and mycophenolate mofetil were administered for GvHD prophylaxis. The subsequent 11 new patients (group B) received the same HDC (BEAM). In contrast to the previous group, fludarabine and TBI were administered just after BEAM, starting on day 2 of BEAM. HSCT was performed on day 6 after start of HDC. G-CSFmobilized peripheral blood was the stem-cell source in all patients. Donors were HLA-matched or one-antigenmismatched siblings or unrelated donors. A comparison of known pre-transplant risk factors is given in Table 1 .
End points of our study included overall and event-free survival, incidence and severity of acute and chronic GvHD, incidence and time to donor-type engraftment and regimen-related toxicity. Non-hematological toxicity was assessed according to the WHO (World Health Organization) criteria. To separate BEAM-related side effects from GvHD, non-hematological toxicity was scored up to the date of engraftment or to the first day of acute GvHD. Acute and chronic GvHD were scored according to the established criteria. 17, 18 Pre-transplant risk characteristics were compared by Fisher's exact test for categorical and by Mann-Whitney U-test for continuous variables between groups A and B. Three-year overall and event-free survival were calculated by Kaplan-Meier estimates and compared by log-rank test. Cumulative incidences of acute and incidence of chronic GvHD were calculated treating death from any cause as a competing risk and compared by Gray test. Severity of acute and chronic GvHD was compared using linear-bylinear association.
Statistical analyses were carried out in SPSS version 12.0 (SPSS Inc., Chicago, IL, USA) and R version 2.2.1 (http:// www.r-project.org).
Results

Patients
Pre-transplant characteristics in the two groups were distributed equally except for a trend to a lower number of pretreatment lines in group B (P ¼ 0.07). Details are given in Table 1 .
Non-hematological toxicity Non-hematological WHO toxicity grades were comparable for skin, mucosa, lung and infectious toxicities. Gut toxicity was more frequent and more severe in group B (median grade 0 (range 0-1) versus 2 (range 1-3, P ¼ 0.01)). Pain/ malaise was, on the other hand, more frequent and severe in group A: median 2.5 (range 0-3) versus 0 (range 0-2, P ¼ 0.01; Figure 1 ).
Engraftment and duration of aplasia
HSCT was administered at median day 28 (range 25-32 days) in group A and on day 6 (range 6-7) in group B after the start of BEAM. Engraftment was on day 11 (range 9-18, group A) and on day 12 (range 9-22, group B, P ¼ 0.77) after HSCT. All patients achieved stable full chimerism. As expected from the design of the study, median time of aplasia was considerably longer in group A compared with group B: 36 (31-43) and 12 (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) days (Po0.001). Owing to the large difference in the duration of aplasia in the two groups, the median length of administration of antibiotics and anti-fungal drugs was 61 versus 26 days (P ¼ 0.016) and 36 versus 24 days (P ¼ 0.49) in group A versus B.
Red-blood cell transfusions (8, range 6-70, versus 6, range 2-59, P ¼ 0.21) and platelet transfusions (12.5, range 6-88, versus 10, range 1-88, P ¼ 0.23) were comparable in the two groups. Shorter time of aplasia and reduced incidence of infectious complications led to a shorter median length of hospital stay in group B than in group A (32 versus 63 days, P ¼ 0.017).
Graft-versus-host disease Cumulative incidence of acute GvHD Xgrade II was 9079% for group A compared with 36715% (P ¼ 0.01) (Figure 2 ). Cumulative incidence of GvHD Xgrade III was 65% in group A compared with 36% in group B. When comparing severity of acute GvHD, a statistical trend toward more severe acute GvHD in group A was observed (P ¼ 0.09) ( Table 2 ). Eighteen patients survived X100 days and were therefore evaluable for chronic GvHD. In group A, all patients at risk developed chronic GvHD, whereas five patients at risk in group B did not develop cGvHD to date (P ¼ 0.04).
Survival
At the last follow-up, seven of 10 (group A) and nine of 11 (group B) patients were alive with a median follow-up of 51 and 20 months, respectively. Since our last report, no deaths or relapses were recorded in group A. In group B, patients UPN 1044 and UPN 1084 died of chronic GvHD 14 and 7 months after HSCT, respectively. Of the 16 patients alive at the last follow-up, 13 were in complete remission. Of the three remaining patients, UPN 914 (group A) who had relapsed 9 months after transplantation has in the meantime been re-transplanted after conditioning with BEAM from a second-HLA identical sibling and is in complete remission 18 months after second HSCT. In group B, patient UPN 1117 had a stable partial response, and patient UPN 1210 had no change (see Table 2 ). No statistical difference in estimated 3-year overall survival was observed between group A and group B patients: 70714 versus 76714% (P ¼ 0.52, Figure 3) . Similarly, estimated 3-year event-free survival was 60715 and 60716% for the two groups. 
Discussion
We report on 21 patients with relapsing or refractory lymphoma undergoing HDC followed by RIC HSCT. We combined the tumor-debulking effect of HDC with the potential GvL effect of allogeneic stem-cell transplantation. The first 10 patients received RIC HSCT, 28 days after BEAM in an attempt to minimize GvHD by temporally separating stem-cell transplantation from the cytokine storm induced by HDC. All patients achieved stable engraftment, tumor control of this regimen was encouraging, but GvHD was higher than expected. We therefore modified our protocol by administering fludarabine and TBI immediately after HDC, omitting the waiting period between BEAM and the transplant conditioning, aiming to reduce time in aplasia and non-hematological toxicity.
In comparison to the original protocol, the modified protocol led to markedly shorter aplasia, reduced time on antibiotics and anti-fungal treatment, and an overall shorter duration of hospitalization compared with the previous cohort. Tumor control was maintained, nine of 11 patients treated with the modified regimen are alive and in complete remission. Toxicity of the modified regimen was comparable to the original protocol, with the exception of an increase in gut toxicity, possibly because of the effect of TBI administered on gut mucosa already damaged by HDC.
Although the association of acute GvHD and gut toxicity induced by the conditioning regimen was reported by others, 19 patients in group B had a lower incidence of acute GvHD. The reason for this observation is unclear. Recent publications indicate that host antigen-presenting cells (APC) survive for a considerable time after HSCT, 20 and hence were unlikely to be depleted after BEAM HDC alone in group A patients. Thus, the remaining host APC may have quickly recovered after HDC, 21, 22 and therefore may have been able to initiate acute GvHD more efficiently in the original delayed transplantation protocol. The cytokine storm as a potential trigger for GvHD was supposedly more present in group B, but despite of that, GvHD was less intensive than group A, indicating that cytokine storm may not have contributed extensively to the triggering of GvHD. The fact that mucositis in all patients of group A at the time of HSCT was healed compared with group B might be an indication that in group A GvHDtarget cells and antigens might have recovered and were contributing more efficiently to the development of GvHD. However, these possible explanations were not experimentally tested in our patients.
Our results compare favorably to historical controls of patients with similar characteristics treated with autologous 23, 24 or standard myeloablative allogeneic HSCT. 25 A concept similar to ours has been advocated by Carella et al., 13 who treated patient with HDC and autologous stem-cell rescue followed by RIC HSCT. The higher rates of relapse occurring with this regimen may in part be explained by contamination of the autologous graft with tumor cells leading to re-infusion of malignant cells after HDC.
To reduce gut toxicity and possibly GvHD, our regimen might be modified by omitting TBI. BEAM plus fludarabine should be expected to be immunosuppressive enough to allow reliable and stable engraftment. Results comparable to ours have been reported on patients treated with BEAM plus CAMPATH, 26, 27 which offers the additional advantages of depleting lymphocytes in the patient and in the graft, combining anti-tumor effects with a partial T-cell depletion and leading to very low rates of GvHD. We preferred a non-T-cell depletion approach to maintain full GvL activity.
Limitations of our study include small patient numbers, and the fact that our cohort comprised mostly younger patients in relatively good general health and is hence not representative of the general population of patients suffering from refractory/relapsing lymphoproliferative diseases. Moreover, our comparison was not randomized and therefore conclusions must be interpreted with care.
To summarize, we show encouraging results of allogeneic HSCT using fludarabine and TBI after BEAM HDC in a population of patients with refractory or relapsing lymphoma. Extended follow-up of our first 10 patients has not shown any late relapses. Immediate transplantation as carried out in group B has led to lower rates of GvHD, shorter time of aplasia, and hence less infectious complications and reduced hospital stay. Despite small patient numbers, our results demonstrate that allogeneic HSCT with standard BEAM conditioning is a viable option for these patients and might be considered earlier in the course of disease.
